Canada markets closed

Second Sight Medical Products, Inc. (EYES)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.3300+0.0600 (+2.64%)
At close: 04:00PM EDT
2.2300 -0.10 (-4.29%)
After hours: 06:54PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close2.2700
Bid2.2000 x 800
Ask2.3400 x 1300
Day's Range2.2700 - 2.3400
52 Week Range1.1400 - 5.2800
Avg. Volume351,691
Market Cap91.823M
Beta (5Y Monthly)2.82
PE Ratio (TTM)N/A
EPS (TTM)-0.2250
Earnings DateJun 26, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire

    Nano Precision Medical Co-Founder and CEO Discusses Proposed Second Sight Merger in Interview to Air on Bloomberg U.S. on the RedChip Money Report®

    LOS ANGELES, April 14, 2022--Second Sight Medical Products, Inc. (NASDAQ: EYES) ("Second Sight"), a recognized global leader in neuromodulation devices for blindness, today announced that an interview with Adam Mendelsohn, Ph.D., Co-Founder and CEO of Nano Precision Medical, Inc. ("NPM"), will air on The RedChip Money Report® on Bloomberg US on April 16 at 7 p.m. Eastern Time (ET). Bloomberg US is available in an estimated 73 million homes across the United States.

  • Business Wire

    Second Sight Medical Products and Nano Precision Medical Announce Merger Agreement to Create Leading Therapeutic Implant Company

    LOS ANGELES & EMERYVILLE, Calif., February 07, 2022--Second Sight Medical Products, Inc. (NASDAQ: EYES) (the "Company" or "Second Sight") and Nano Precision Medical, Inc. ("NPM"), today announced that they have entered into a definitive agreement under which privately held NPM will merge with a wholly owned subsidiary of Second Sight in an all-stock transaction. NPM will be the surviving company and owned by Second Sight. The resulting company will focus on development of innovative drug and dev

  • Business Wire

    Second Sight Medical Products Announces a New NIH Grant Supplement for Its Orion Study

    LOS ANGELES, August 11, 2021--Second Sight Medical Products, Inc. (NASDAQ: EYES) (the "Company" or "Second Sight"), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, announces that the Company received a grant supplement from the National Institutes of Health (NIH) to fund a qualitative study to gather critical insights into how profoundly blind people weigh the risks and benefits of visual neuroprostheses